← Leaderboards
John K. Walker
Saint Louis University
$4,990,758
Attributed
$14,677,824
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,677,824 · 7
By mechanism
R01$11,780,464 · 4
R61$1,511,970 · 1
T32$1,385,390 · 2
Top collaborators
- Thomas P Burris10 shared
- Valentin V Rybenkov6 shared
- Helen I. Zgurskaya6 shared
- Sandrasegaram Gnanakaran5 shared
- Paolo Ruggerone5 shared
- Gina L.C. Yosten5 shared
- Terrance M Egan4 shared
- Anutosh Chakraborty2 shared
Most similar at Saint Louis University
Same institution · by research overlap
- Christopher K Arnatt$1,774,864
- Gina L.c. Yosten$4,545,643
Others in their field
Top investigators on “Property”
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
Research focus
PropertyPharmaceutical PreparationsCellsGrantLigandsFamilyTrainingReceptorIn VivoStructure-Activity RelationshipClinicAgonistHuman DiseaseAnimalsDrug DevelopmentPhysiological ProcessesNuclear ReceptorsOrphanDrug KineticsAffinityTranscription FactorPharmacologyAreaNuclear Orphan Receptor
Grant awards (24)
Atlas of efflux and permeation determinants to advance antibacterial therapeutic discovery$1,120,070
R01 · FY2025 · AI
Pharmacological Sciences Training Grant$246,325
T32 · FY2025 · GM · contact PI
Development of selective GPR34 antagonists for the treatment of neuropathic pain$1,511,970
R61 · FY2024 · NS
Pharmacological Sciences Training Grant$255,280
T32 · FY2024 · GM
Pharmacological Sciences Training Grant$245,868
T32 · FY2023 · GM
Optimization of efflux avoidance and inhibition for antibiotic development$1,099,291
R01 · FY2022 · AI
Pharmacological Sciences Training Grant$240,786
T32 · FY2022 · GM
Optimization of efflux avoidance and inhibition for antibiotic development$1,106,111
R01 · FY2021 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,048,793
R01 · FY2020 · AI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$502,895
R01 · FY2020 · MH
Pharmacological Sciences Training Grant$53,086
T32 · FY2020 · GM
Optimization of efflux avoidance and inhibition for antibiotic development$1,056,326
R01 · FY2019 · AI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$470,731
R01 · FY2019 · MH
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$402,527
R01 · FY2019 · MH
Pharmacological Sciences Training Grant$173,085
T32 · FY2019 · GM
Optimization of efflux avoidance and inhibition for antibiotic development$1,421,601
R01 · FY2018 · AI
ERRgamma Agonists to Treat Muscular Dystrophy$536,587
R01 · FY2018 · AR
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$536,393
R01 · FY2018 · MH
Pharmacological Sciences Training Grant$170,960
T32 · FY2018 · GM
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$59,600
R01 · FY2018 · MH
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$595,993
R01 · FY2017 · MH
ERRgamma Agonists to Treat Muscular Dystrophy$580,666
R01 · FY2017 · AR
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$662,214
R01 · FY2016 · MH
ERRgamma Agonists to Treat Muscular Dystrophy$580,666
R01 · FY2016 · AR